Clinical Trial Update: Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in combination with irinotecan for recurrent or refractory gliomas; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED